From the Editor

Apr 01, 2002
Pharmaceutical Executive
Perseverance furthers. Those two unadorned words from the ancient I Ching were all that first entered my startled mind as I accepted the Oscar of business-to-business media-the Grand Neal Award.
Mar 01, 2002
Pharmaceutical Executive
How quickly the promise of pharmacogenomics and other medical miracles materializes may soon depend more on war-driven politics than science. Only free exchange of scientific information in public arenas such as peer-review journals makes progress possible. But now in the United States, long an avatar of freedom and progress, the government's war on terror threatens to subjugate that tradition in a new culture of secrecy.
Feb 01, 2002
Pharmaceutical Executive
Who, or what, creates wealth? Answering that question has become as much political football as economic theory. Last month, the US president reminded us that government does not make wealth but, at best, fosters a climate conducive to it. The old-left idea that workers create and should share equally in the fruits of production has long since died of exhaustion. By process of elimination, the only apparent answer remaining belongs to idealistic capitalists, who herald the enterprising companies from which all wealth "obviously" flows-for most of us, as paychecks.
Jan 01, 2002
Pharmaceutical Executive
Small items sometimes bring big news. Merely the briefest of summaries, this nugget nevertheless caught my attention-describing a survey of young people's career aspirations. It reported a sudden drop off in US college graduates contemplating jobs in the pharmaceutical industry, as measured against the previous five years. Why? Bad press.
Dec 01, 2001
Pharmaceutical Executive
No one can pinpoint the precise instant it happened, but the dull cloud of our universe suddenly cleared. About a half-billion years had gone by since the Big Bang, finally giving the condensing proto-stars and quasars enough time to sweep a veil of dust from the young cosmos. Their light then penetrated the darkness and, along with that of countless other spawning suns, has traveled the skies ever since.
Oct 01, 2001
Pharmaceutical Executive
I heard the first bird of the morning whistling to his lover. Their small wings owned the sky again while the people fled for cover.
Sep 01, 2001
Pharmaceutical Executive
In religion, belief comes first. In science, it comes last. And in politics, as in publishing, you can often find it for sale.
Aug 01, 2001
Pharmaceutical Executive
That marketing should begin early in product development has become a truism in the pharma industry. But as a statement on its own, it sheds little light. What does it mean to begin? At what point do marketers insert themselves into the process? To what end do they enter where once only scientists trod? And, the ultimate question—which the truism fails to answer—how might their intrusion affect the lives of patients, in trial or thereafter?
Jul 01, 2001
Pharmaceutical Executive
Is the pharmaceutical industry surrounded by its critics? Can the industry be liberated from the moral bind others want to impose on it? Those are questions I asked and attempted to answer in two recent editorials (PE April and June 2001). Actually, the simple answer was yes to both. But other answers prove more complex.
Jun 01, 2001
Pharmaceutical Executive
I intended to write an entirely different column this month. Something like, What the Bush administration has done for you-the pharmaceutical industry-lately. Such as making it harder to do stem-cell research and pursuing an investigation into antigeneric activities. But something else happened. My father died. Now I have no room left in my mind or heart for other matters.
native1_300x100
lorem ipsum